ISPOR North America 2014 Papers
Posters and papers presented by Access Partnership at ISPOR NA 2014
Medical devices in Japan – a market access labyrinth?
Progress in personalized medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in molecular diagnostics (mdx)
International HTA referencing – a reality?
Biosimilars: friends or foe for payers, physicians and manufacturers?
The real impact of quality of life endpoints on market access decisions – a case study of oncology products
ISPOR North America 2013 Papers
Posters and papers presented by Access Partnership at ISPOR NA 2013
Challenges for Preparing for Loss of Exclusivity
Variability in Local Uptake and Patient Access to Medicines-Implementation of Scottish Medicines Consortium Guidelines
An Investigation into the Key Drivers Influencing the Decision-Making of the Scottish Medicines Consortium
Transformation of Services and Care Pathway Redesign in the NHS: Further Reforms in Health Policy
ISPOR Europe 2012 Papers
Posters and papers presented by Access Partnership at ISPOR Europe 2012
Drivers of pricing and market access decisions - Examples in selected countries
How will the new NHS changes in England impact the implementation of risk sharing schemes for oncology treatments
How will the new NHS decentralised reforms impact on access to medicines in England?
Orphan drug pricing and access - current situation and future trends